Yabao Pharmaceuticals and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China
BEIJING & MONMOUTH JUNCTION, N.J.–(BUSINESS WIRE)–Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351) and
Sciecure Pharma Inc. today announced a strategic partnership to
co-develop, manufacture and commercialize high technological barrier
generics medicines for both the U.S. and China markets.
Under the terms of the agreement, Yabao will exclusively own rights to
commercialize certain Sciecure Pharma-developed products in China and to
manufacture for both the U.S. and China markets, while Sciecure Pharma
will retain rights to commercialize in U.S. and all other markets.
Financial terms were not disclosed.
“Yabao is pleased to collaborate with Sciecure Pharma, a dynamic company
with extensive drug development expertise and know-how on high
technological barrier controlled release formulation, to synergize with
Yabao’s cGMP manufacturing and leading commercialization capabilities in
China,” commented Dr. Peng Wang, President of R&D, Yabao Pharmaceutical
Co. “Yabao is actively partnering with leading overseas companies to
bring in and deliver high quality medicines with unmet needs in China.
This partnership also demonstrates that Yabao’s competitive R&D and
manufacturing have expanded into developed markets.”
“We are pleased to work with a leading Chinese pharma company like
Yabao,” said Dr. Nuo (Nolan) Wang, CEO of Sciecure Pharma Inc. “With
current stormy policy changes in the pharmaceutical sector in China, the
demand for high quality pharmaceutical products is rapidly growing.
Sciecure Pharma is uniquely positioned to meet such demand through
strategic partnering. We trust that our collaboration with Yabao will be
synergistic and successful in quickly bringing high quality pharma
products to patients in China.”
About Yabao Pharmaceutical Co.
Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading
China pharmaceutical company with fully integrated development,
manufacturing, and commercialization capabilities. Yabao recently has
been pursuing strategic development and commercialization partnerships
to bring high quality innovative or generic medicines into China. In
addition to strong clinical and regulatory capabilities, Yabao has
extensive expertise in formulation and API production and meets current
Good Manufacturing Practice (cGMP) requirements with two manufacturing
sites approved by U.S. FDA and a European agency, respectively. For more
information about Yabao Pharmaceutical Co., please visit www.yabao.com.cn.
About Sciecure Pharma Inc
Sciecure Pharma, Inc. is an emerging U.S. based specialty pharmaceutical
company with a focus on developing high barrier, technology based,
bioequivalent generic and innovative drug products for regulated
markets. Sciecure Pharma collaborates through strategic partnership with
other pharmaceutical companies in the United States and China in product
development, manufacturing, and sales.
Contacts
Yabao Contact
Ms. Weina Liu, +86-10-5808-6285
liuweina@yabaoyaoye.com
or
Sciecure
Contact
Nuo (Nolan) Wang, +001-908-723-1209
nolan.wang@sciecurepharma.com
